Tonum Health

Tonum is a clinical-stage biotechnology company focused on developing next-generation oral therapies for metabolic diseases, specifically targeting obesity and metabolic dysfunction-associated steatohepatitis (MASH). Founded by Mark Pruzanski, the former CEO of Intercept Pharmaceuticals, the company aims to provide potent and well-tolerated oral alternatives to current injectable metabolic treatments. Tonum leverages deep expertise in metabolic signaling and bile acid biology to address the global epidemic of metabolic disorders. The company is backed by a prominent group of investors, including ARCH Venture Partners and GV, and is rapidly advancing its lead programs through early clinical trials. Its mission is to transform the treatment landscape for metabolic health by delivering convenient and effective pharmacological solutions.